Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1001/jamacardio.2017.0294 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Management, Flow, and Outcomes of Patients with Aortic Stenosis Followed by a Heart Valve Clinic: The Untold "Behind the Scene" from a High-Volume, Real-World Experience.
J Clin Med
January 2025
Department of Cardiovascular Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy.
According to current guidelines, patients with heart valve disease should be followed by Heart Valve Clinics (HVCs). Regular quality analysis is a major prerequisite of an HVC's program, but few data have been reported so far. We retrospectively collected patients with isolated, native aortic valve stenosis who had been visited in our HVC at least once between 2021 and 2024.
View Article and Find Full Text PDFChest Pain and ST-Segment Elevation: Angiosarcoma Discovered With Coronary Angiography.
JACC Case Rep
December 2024
Rush University Medical Center, Chicago, Illinois, USA.
Primary cardiac angiosarcomas are rare malignant tumors that can cause chest pain and heart failure symptoms. They can be diagnosed using multimodality imaging, primarily echocardiogram, with formal diagnosis requiring biopsy. A 56-year-old man with history of hypertension and dyslipidemia presented with acute crushing chest pain and shortness of breath.
View Article and Find Full Text PDFTranscatheter Tricuspid Valve Clinical Trials: Incomplete Data and FDA-Approved Devices.
Struct Heart
November 2024
Department of Cardiovascular Medicine, Intermountain Medical Center, Murray, UT.
Each reviewed trial of transcatheter tricuspid valve intervention demonstrated clinically meaningful improvement in Kansas City Cardiomyopathy Questionnaire (KCCQ)-defined quality of life and favorable right ventricular remodeling. KCCQ correlates with tricuspid regurgitation (TR) reduction, heart failure hospitalization, and mortality. Change in KCCQ is therefore meaningful both as a measure of quality of life and as a surrogate endpoint of the impact of TV interventions.
View Article and Find Full Text PDFAntibodies directed at the amyloid-β peptide offer the prospect of disease-modifying therapy for early-stage Alzheimer disease but also carry the risk of brain edema or bleeding events, collectively designated amyloid-related imaging abnormalities. Introduction of the antiamyloid immunotherapies into practice is therefore likely to present a new set of questions for clinicians treating patients with cerebrovascular disease: Which manifestations of cerebrovascular disease should preclude, or permit, antibody treatment? Is it safe to prescribe amyloid immunotherapies to individuals who require antithrombotic treatment, or to administer thrombolysis to antibody-treated individuals with acute stroke? How should severe amyloid-related imaging abnormalities be managed? This science advisory summarizes the data and key considerations to guide these challenging decisions as the medical community collects further data and experience with these groundbreaking agents.
View Article and Find Full Text PDFTAVI patients with bystander coronary artery disease should receive PCI: pros and cons.
EuroIntervention
November 2024
Cardiovascular Department, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!